Tabernanthe iboga

MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

Retrieved on:

Tuesday, July 27, 2021

Psychoactive drugs, Entheogens, Branches of biology, NMDA receptor antagonists, Indole alkaloids, Drug rehabilitation, Ibogaine, Tabernanthe iboga, Legal status of ibogaine by country

During this stage, the Company will be assessing the quality of the synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing.

Key Points:

During this stage, the Company will be assessing the quality of the synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing.
As first announced on July 13, 2021, MINDCURE has also filed patent applications for two routes of chemical synthesis of ibogaine.
Ibogaine is a psychoactive substance that can be found naturally in the roots of the iboga tree, which grows in Africa.
"We are now one step closer towards our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes," said Kelsey Ramsden, President and CEO of MINDCURE.

MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound

Retrieved on:

Tuesday, July 13, 2021

Psychoactive drugs, Branches of biology, Entheogens, Drugs, NMDA receptor antagonists, Indole alkaloids, Ibogaine, Tryptamines, Tabernanthe iboga, Psychedelic drug, Psychedelic therapy, Organic chemistry

The Company has filed patent applications for two chemical synthesis routes, both of which successfully produced ibogaine.

Key Points:

The Company has filed patent applications for two chemical synthesis routes, both of which successfully produced ibogaine.
The identified routes may provide advantages of improved isomeric purity, increased chiral purity, and more easily isolated intermediate compounds.
The two chemical synthesis routes are currently being assessed to determine which one will be selected for further development first.
"Manufacturing synthetic ibogaine and patenting our process would create the opportunity for synthetic ibogaine to be used by researchers conducting clinical trials and, eventually, by clinicians providing psychedelic therapy.

Dr. Jeffrey Kamlet Internationally Recognized Expert on Cardiac Safety in Ibogaine Treatment Joins Ehave as Chief Medical Officer

Retrieved on:

Tuesday, June 15, 2021

Psychoactive drugs, Drugs, Neurochemistry, Entheogens, NMDA receptor antagonists, Nicotinic antagonists, Ibogaine, Tryptamines, Tabernanthe iboga, Ketamine

Ketamine treatments on anxiety, depression and PTSD using brain mapping technology, stated Ben Kaplan, CEO of Ehave.

Key Points:

Ketamine treatments on anxiety, depression and PTSD using brain mapping technology, stated Ben Kaplan, CEO of Ehave.
Dr. Jeffrey Kamlet, M.D, FASAM, DABAM is recognized as the worlds expert on cardiac safety in ibogaine treatment.
Dr. Kamlet served as the Global Ibogaine Therapy Alliance's Chief Medical Advisor, as well as Editor in Chief on the Global Ibogaine Therapy Alliance's Clinical Guidelines for Ibogaine-Assisted Detoxification.
Additionally, he has worked as an Associate Director and Medical Director for several emergency departments in Southern Florida as well EMS Medical Director for the City of Pembroke Park, FL.

MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

Retrieved on:

Thursday, June 3, 2021

Entheogens, Psychoactive drugs, Branches of biology, Drugs, Drug rehabilitation, Nicotinic antagonists, Indole alkaloids, NMDA receptor antagonists, Ibogaine, Tabernanthe iboga, Pharmaceutical industry, Synthetic

Throughout this proof-of-concept stage, MINDCURE completed the chemistry and route scouting and successfully manufactured synthetic ibogaine.

Key Points:

Throughout this proof-of-concept stage, MINDCURE completed the chemistry and route scouting and successfully manufactured synthetic ibogaine.
In the coming weeks, MINDCURE will focus on the scale-up process by launching stage two of the manufacturing process for pharmaceutical grade ibogaine.
By manufacturing synthetic ibogaine, MINDCURE's research team will have access to a sustainable and high-quality drug supply, ensuring consistent dosing and reliable results.
"We have successfully completed the critical first step in our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes," said Kelsey Ramsden, President and CEO of MINDCURE.

Ibogaine by David Dardashti Recommends Ibogaine Treatments to be Tailored to Individuals

Retrieved on:

Friday, April 9, 2021

Psychoactive drugs, Entheogens, Branches of biology, Drugs, NMDA receptor antagonists, Indole alkaloids, Drug rehabilitation, Nicotinic antagonists, Ibogaine, Tabernanthe iboga, Howard Lotsof

Ibogaine hydrochloride has proven to be the most effective treatment for opiate addiction, yet complications still arise.

Key Points:

Ibogaine hydrochloride has proven to be the most effective treatment for opiate addiction, yet complications still arise.
They simply have a one size fits all method of Ibogaine treatment.
Ibogaine By David Dardashti has worked many years providing the most effective full treatment of ibogaine hydrochloride, having treated thousands of patients.
Ibogaine By David Dardashti has integrated many mathematical models, using principles of calculus, algebra, and statistics, used to effectively measure and predict the outcome of a single person's reaction to the ibogaine.

MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research

Retrieved on:

Wednesday, March 3, 2021

Entheogens, Psychoactive drugs, Branches of biology, Drugs, NMDA receptor antagonists, Drug rehabilitation, Nicotinic antagonists, Ibogaine, Tryptamines, Tabernanthe iboga

MINDCURE recognizes the importance of sustainability, excellence, and reliability regarding the materials it uses in product development and research.

Key Points:

MINDCURE recognizes the importance of sustainability, excellence, and reliability regarding the materials it uses in product development and research.
By manufacturing ibogaine, MINDCURE's research team will have access to a predictable and standardized supply of synthetic ibogaine, while ensuring consistent dosing and reliable results.
Ibogaine has unique and broad actions in the brain, affecting multiple receptors and neurotransmitter systems.
Ibogaine offers incredible therapeutic potential, especially in the context of neuroregeneration," said Dr. Ryan Hartwell, Chief Science Officer, MINDCURE.

Researchers Delve Into Psychedelics in Search of Novel Therapies

Retrieved on:

Thursday, May 21, 2020

Psychoactive drugs, Entheogens, Branches of biology, Drugs, Drug rehabilitation, Ibogaine, Tryptamines, Tabernanthe iboga, Hallucinogen, Therapy, Behaviour therapy

For example, the company Mind Med owns the intellectual property around a drug known as 18-MC, a synthetic form of the hallucinogenic drug Ibogaine.

Key Points:

For example, the company Mind Med owns the intellectual property around a drug known as 18-MC, a synthetic form of the hallucinogenic drug Ibogaine.
But there are certainly companies out there looking for money, and it looks like there's people willing to fund them."
Mindleap is uniquely designed to meet the needs of the over 90+ psychedelic clinics and 30 million underground psychedelic users.
Unfortunately, current ASD management options are restricted to cognitive behavioral therapy and a small number of approved pharmacologic treatments, highlighting the substantial unmet need for novel therapies in this population.

Researchers Delve Into Psychedelics in Search of Novel Therapies

Retrieved on:

Thursday, May 21, 2020

Psychoactive drugs, Entheogens, Branches of biology, Drugs, Drug rehabilitation, Ibogaine, Tryptamines, Tabernanthe iboga, Hallucinogen, Therapy, Behaviour therapy

For example, the company Mind Med owns the intellectual property around a drug known as 18-MC, a synthetic form of the hallucinogenic drug Ibogaine.

Key Points:

For example, the company Mind Med owns the intellectual property around a drug known as 18-MC, a synthetic form of the hallucinogenic drug Ibogaine.
But there are certainly companies out there looking for money, and it looks like there's people willing to fund them."
Mindleap is uniquely designed to meet the needs of the over 90+ psychedelic clinics and 30 million underground psychedelic users.
Unfortunately, current ASD management options are restricted to cognitive behavioral therapy and a small number of approved pharmacologic treatments, highlighting the substantial unmet need for novel therapies in this population.

Graph Blockchain Provides Additional Information on Shroom Street Team and Corporate Objectives

Retrieved on:

Tuesday, December 3, 2019

Psychoactive drugs, Entheogens, Apocynaceae, Shrubs, Tabernanthe iboga, Ayahuasca

TORONTO, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Graph Blockchain Inc. (Graph or Company) (CSE: GBLC)is pleased to provide additional information on the previously announced proposed acquisition of Shroom Street Limited.

Key Points:

TORONTO, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Graph Blockchain Inc. (Graph or Company) (CSE: GBLC)is pleased to provide additional information on the previously announced proposed acquisition of Shroom Street Limited.
Shroom Street is pleased to share that it has added expert psychedelic industry professionals to the media team.
Eric writes and edits an ayahuasca website, https://kahpi.net, and an iboga public information campaign, https://awake.net.
We are excited to see Shroom Street add such talented industry professionals to the team.

Rehab That Works - Introducing Tabula Rasa Retreat

Retrieved on:

Tuesday, September 25, 2018

Neurochemistry, Entheogens, Neuroscience, Cell signaling, NMDA receptor antagonists, Drug rehabilitation, Ibogaine, Tryptamines, Tabernanthe iboga, Tabula, Rasa, Addiction

With addiction to stimulants and opiates (from heroin to OxyContin) at an all-time high, Tabula Rasa Retreat - https://tabularasaretreat.com is a unique rehab centre that uses plant medicine in a medicalised and holistic therapeutic setting.

Key Points:

With addiction to stimulants and opiates (from heroin to OxyContin) at an all-time high, Tabula Rasa Retreat - https://tabularasaretreat.com is a unique rehab centre that uses plant medicine in a medicalised and holistic therapeutic setting.
Based in the serene surrounds of rural Portugal, Tabula Rasa Retreat's mission is to help addicts on the road to recovery with the help of the powerful addiction-interrupting ibogaine plant medicine.
Alvaro de Ferranti, the co-founder of the Tabula Rasa Retreat stated: "Iboga, a bark extract from West Central Africa, is the most effective way of interrupting addiction on the planet."
"We didn't set up Tabula Rasa to get rich, but to prove that ibogaine-assisted therapy can be done right.